| # | Capability | Input | Output |
|---|---|---|---|
| --- | ----------- | ------- | -------- |
| 1 | Disease Outbreak Surveillance | Country / pathogen / time range | Cases, R0, CFR, geographic spread, genomic variants, WHO/CDC advisories |
| 2 | Clinical Trial Intelligence | Drug / indication / phase / sponsor | Trial design, enrollment, endpoints, results, N sites, cross-referenced across CT.gov/EU-CTR |
| 3 | Drug Pipeline Analysis | Therapeutic area / mechanism / company | Phase progression, likelihood-of-approval, competitive landscape, patent expiry, market forecast |
| 4 | Health Systems Benchmarking | Countries (2-10) | Expenditure %GDP, UHC index, outcomes (LE/HALE), workforce density, hospital beds, digital maturity |
| 5 | Biomedical Literature Synthesis | Topic / PICOS query | Systematic review-style summary, strength-of-evidence grading, conflicting findings flagged |
| 6 | Regulatory & Reimbursement Landscape | Drug/device + jurisdiction | Approval pathway, HTA assessment, pricing & access, post-market surveillance requirements |
| 7 | Longevity & Aging Science Monitor | Intervention / pathway | Preclinical–clinical pipeline, mechanism-of-action, biomarker effects, safety signals |
| 8 | Digital Health & AI MedTech Radar | Category + region | Regulatory classification (SaMD), clinical evidence maturity, reimbursement status, competitive scan |
| 9 | Vaccine Development Dashboard | Pathogen / platform (mRNA/viral vector/etc) | Phase status, efficacy data, manufacturing capacity, cold-chain requirements, variant coverage |
| 10 | Health Policy Comparative Analysis | Policy area + countries | Legal framework, funding mechanism, implementation status, outcomes data, stakeholder positions |
User Query
│
├─ [Step 1] Triage query → identify domain(s) from 9 disease categories + 4 analysis types
│
├─ [Step 2] Execute parallel search across relevant sources:
│ └─ Official sources (WHO GHO, CDC, NIH/FDA/EMA) for regulatory + epidemiological
│ └─ Trial registries (CT.gov, EU-CTR) for clinical pipeline
│ └─ Literature (PubMed, medRxiv) for evidence base
│ └─ Analytics (IHME GBD, Our World in Data) for population-level metrics
│
├─ [Step 3] Data fusion: cross-reference across sources, flag discrepancies
│
├─ [Step 4] Quality assessment: GRADE framework for evidence, QC for data freshness (<30-day recency preferred)
│
├─ [Step 5] Structured output generation per domain template
│
└─ [Step 6] Cite all sources with URLs, publish dates, and data vintage
| Field | Content |
|---|---|
| ------- | --------- |
| Pathogen/Syndrome | Name, taxonomy, known variants |
| Epidemiological Snapshot | Cases, deaths, CFR, R0/Rt, doubling time |
| Geographic Distribution | Affected regions, hot zones, importation risk |
| Countermeasures | Vaccines (available/in-development), therapeutics, diagnostics |
| Public Health Measures | WHO PHEIC status, travel advisories, NPIs |
| Sources | URLs + retrieval dates |
| Drug (Company) | Mechanism | Phase | Key Endpoints | PDUFA/Decision Date | LoA Est. | Notes |
|---|---|---|---|---|---|---|
| ---------------- | ---------- | ------- | --------------- | --------------------- | ---------- | ------- |
| ... | ... | ... | ... | ... | ... | ... |
| Indicator | Country A | Country B | Country C | OECD Avg |
|---|---|---|---|---|
| ----------- | ----------- | ----------- | ----------- | ---------- |
| Health exp. %GDP | ||||
| UHC Service Coverage Index | ||||
| Life expectancy at birth | ||||
| Physicians per 1,000 | ||||
| Hospital beds per 1,000 | ||||
| Out-of-pocket % health spend |
User: "What's the competitive landscape for GLP-1 receptor agonists beyond obesity?"
Output: Table of Phase 2/3 trials for cardiovascular, NASH/MASH, kidney disease, Alzheimer's, addiction indications; partnership/collaboration map; market size projections by indication.
User: "Track the latest on H5N1 avian influenza in 2026"
Output: WHO/CDC case counts, mammal spillover events, vaccine stockpile status, genomic surveillance findings, pandemic risk assessment tier.
User: "Compare US, UK, and Singapore health systems on efficiency and outcomes"
Output: Multi-indicator comparison table; spending vs. outcomes scatter analysis; key structural differences (funding model, gatekeeping, provider payment).
Data Base: references/health_sources.json — 12 authoritative data sources, 9 disease domains, 8 health system countries, drug development phase reference data.
Last Updated: June 2026
Free Tier: Available. This skill aggregates public health intelligence; no proprietary data accessed.
（内容由AI生成，仅供参考）
共 1 个版本